2026-03-06 23:59 UTC
# Ledger Entry — Cycle X Pipeline Addendum II: No Transactions, Portfolio Unchanged

## Sterling Capital Management | Bookkeeper

---

## Summary

**IC Memo Booked**: 2026-03-06_ic-memo-3.md (Cycle X Pipeline Addendum II, FINAL 23:59 UTC)

**Portfolio Changes**: NONE. All 10 active positions remain HOLD at current allocations.

**Transactions Executed**: None.

**Capital Deployed**: Zero.

**Active Portfolio State**: Identical to prior booking (2026-03-06_ledger-entry.md at 22:15 UTC).

---

## Memo Directive

The PM explicitly directs (Section: Directives Issued, To Bookkeeper, Item 10):

> "No transactions this cycle. Active portfolio unchanged. All 10 positions held at current allocations. Cash at 20%."

**Consequence**: Ledger remains unchanged. Current-holdings.json does not require update.

---

## Current Portfolio (Unchanged)

| # | Ticker | Sector | Allocation | Price (Mar 6 Close) | Target | Stop | R/R | Status |
|---|--------|--------|---|---|---|---|---|---|
| 1 | VRT | AI Infrastructure | 13.0% | $241.78 | $310 | $210 | 2.14:1 | HOLD |
| 2 | LHX | Defense/Aerospace | 12.0% | $366.61 | $450 | $320 | 1.79:1 | HOLD |
| 3 | CEG | Power Generation | 10.0% | $319.06 | $410/$460 | $275 | 2.07:1 | HOLD |
| 4 | VST | Power Generation | 8.0% | ~$163 | $235 | $145 | 4.00:1 | HOLD |
| 5 | INTC | Semiconductors | 8.0% | ~$44.50 | $65 | $34 | 1.95:1 | HOLD (catalyst) |
| 6 | AVGO | AI Infrastructure | 8.0% | ~$336 | $460 | $270 | 1.88:1 | HOLD |
| 7 | IPGP | Industrial Photonics | 7.0% | ~$124 | $180 | $100 | 2.33:1 | HOLD |
| 8 | AEM | Gold Mining | 5.0% | ~$222 | $290 | $195 | 2.52:1 | HOLD |
| 9 | INOD | AI Services | 5.0% | ~$46 | $72 | $36 | 2.60:1 | HOLD |
| 10 | FRO | Tanker Shipping | 4.0% | $34.56 | $46 | $33 | 7.36:1 | HOLD (stop alert) |

**Total Deployed**: 80.0% | **Cash**: 20.0% | **Portfolio Weighted R/R**: ~2.3:1 | **VaR 95% (VIX 29)**: ~3.02%

---

## Conditional Pipeline Restructuring (Governance Update Only)

### Four New Pitches Evaluated

All prices verified by Risk Manager via StockAnalysis.com at close March 6, 2026.

#### Pitch 1: Marvell Technology (MRVL) — REJECTED (Final, Risk-Confirmed)

- **Price**: $87.88 close | **Entry**: $78-92 | **Target**: $121 | **Stop**: $63
- **R/R**: 1.33:1 at regular close (below 1.5:1 minimum)
- **Rejection Grounds (All Risk-Confirmed)**:
  1. R/R 1.33:1 below minimum; insufficient asymmetry
  2. Trainium 3 design loss to Alchip (Amazon awarded Trainium 3/4 to Alchip, Marvell on legacy 2.5)
  3. Semiconductor concentration: AVGO 8% + INTC 8% + MRVL 3% = 19-20% (excessive at VIX 29+)
  4. Post-16-18% gap-up entry violates execution discipline
  5. AWS customer concentration ~56% (existential, not diversifying; customer transitioning to competitor)
- **Re-pitch Criteria**: Price <$80 (R/R reaches 2:1+), Alchip/Trainium dynamics explicitly addressed with primary-source evidence, semiconductor slot opens through INTC or AVGO exit.
- **Status**: FINAL. Do not reconsider unless criteria met.

#### Pitch 2: Equinix (EQIX) — CONDITIONAL APPROVAL (Final, Priority 9)

- **Price**: $937.20 | **Entry**: $870-900 | **Target**: $1,080 | **Stop**: $800
- **R/R**: 1.04:1 at current price; 1.69:1 at $900; 2.00:1 at $870
- **Thesis**: EQIX fills AI infrastructure stack gap (chips + power + physical buildings). Record bookings (+42% QoQ), $430B+ hyperscaler capex, Moody's Baa1 upgrade, 2.2% dividend.
- **Chain Concern**: EQIX correlated with VRT (0.50-0.65), AVGO (0.40-0.55), CEG (0.35-0.50). Deployment pushes AI-adjacent exposure to 42% (accepted as hard cap).
- **Entry Conditions (ALL required)**:
  1. EQIX at or below $900 (R/R ~1.69:1) OR 10Y yield below 3.75% (target revises to $1,150+)
  2. Slot availability
  3. VIX below 22 for 2+ sessions
  4. Q1 2026 AFFO growth confirms 9%+ trajectory
  5. Post-deployment AI-adjacent exposure must not exceed 42%
- **Target Allocation**: 3-4% of NAV
- **Status**: CONDITIONAL. Priority 9 of 10 in pipeline.

#### Pitch 3: Elevance Health (ELV) — CONDITIONAL APPROVAL (Final, Tier 1B, Priority Elevated)

- **Price**: $289.64 | **Entry**: $275-298 (revised upper bound) | **Target**: $370 | **Stop**: $250
- **R/R**: 2.08:1 at current price
- **Thesis**: Highest-conviction new conditional. Zero correlation (0.00-0.10 portfolio-weighted). VaR-reducing (add 5-7% reduces portfolio VaR by 0.05-0.08 pp due to 0.47 beta). Stress tests improve across all bearish scenarios (GFC +0.7 pp, COVID +0.6 pp, Rates +0.4 pp, Recession +0.5 pp). Sum-of-parts: Carelon at 15x operating income ~$51B (80% of market cap); market assigns near-zero value to $167B Health Benefits franchise. Catalyst: CMS 2027 final rate by April 6 (historical precedent: 2026 rate exceeded advance notice by 2.83 pp). Insider validation: Seth Klarman 8.43% (Baupost), Sequoia Fund 5.13%, Director purchase at $289.84 on March 5.
- **R/R Degradation Framework** (Risk Flag 2):
  - Max entry for 1.5:1 R/R at $370 target: $298
  - If entry above $298: Target must revise upward
  - Analyst consensus $386.59 supports entry up to ~$305
  - If entry above $305: Deployment suspended pending revised thesis
- **Entry Conditions (ALL required)**:
  1. CMS 2027 final rate announcement (by April 6) at 2.0% or above
  2. Post-rate price confirms entry below $298 (maintaining 1.5:1 R/R) OR entry $298-305 with revised target $387+ (analyst consensus support)
  3. Slot availability (through exit, stop-out, or VRT resize)
  4. VIX below 22 for 2+ sessions (may be waived if CMS rate overwhelmingly positive AND VaR-reducing)
- **Alternative Deployment Path**: If both ELV and LLY catalysts fire in April 6-10 window, LLY deploys first (Priority 1). ELV queues for next slot. If two slots open simultaneously (FRO stop-out + VRT resize), both deploy at 5% each (cash to 8% floor).
- **Target Allocation**: 5-7% of NAV
- **Status**: CONDITIONAL. Elevated to Tier 1B deployment priority (second-tier, after FRO/LLY tier).

#### Pitch 4: Samsara (IOT) — CONDITIONAL APPROVAL (Final, Classification Corrected, Priority 8)

- **Price**: $35.36 | **Entry**: $30-33 (tightened from $33-37) | **Target**: $48 | **Stop**: $27
- **R/R**: 1.51:1 at current price; 2.50:1 at $33 entry; 3.50:1 at $30 entry
- **Thesis**: AI application-layer diversifier. Fleet optimization demand counter-cyclical; however, stock price pro-cyclical (beta 1.60). Stock declined 27% from 52-week high during period when fleet demand was strengthening. IOT is NOT a portfolio hedge.
- **Classification Corrected**: IOT's value is (a) AI application-layer diversification (0% current exposure), (b) low end-market correlation with data center/power/defense/gold, and (c) profitability inflection with durable growth. NOT counter-cyclical portfolio hedge. ELV and LLY serve hedge function.
- **VaR Analysis**:
  - IOT at 5%: VaR 95% increases 0.25 pp at VIX 27 (2.77% to 3.02%) — VaR-increasing
  - At VIX 20 (deployment condition): VaR increases 0.15 pp (1.68% to 1.83%, within guideline)
  - Stress tests unfavorable in tail scenarios (GFC -1.1 pp, COVID -0.8 pp), favorable in oil-shock (+0.5 pp)
- **Price Action**: Historical analysis of 15%+ gap-ups suggests 30-day median pullback of 5-10%, implying $31.70-$33.60 consolidation range. PM's $33 pullback condition is achievable.
- **Entry Conditions (ALL required)**:
  1. IOT price at or below $33 (R/R reaches 2.50:1)
  2. VIX below 22 for 2+ sessions
  3. Slot availability
  4. Q1 FY2027 revenue guidance reaffirmed or exceeded
  5. IOT must not coincide with VaR-increasing deployments (no simultaneous VRT or INOD upsize)
- **Target Allocation**: 5% of NAV
- **Status**: CONDITIONAL. Priority 8 of 10. Entry conditions stringent but achievable.

### Summary: Final Pipeline Review

| # | Ticker | Analyst | R/R at Current | R/R at Entry | Decision | Target Alloc | Key Condition |
|---|--------|---------|---|---|---|---|---|
| 1 | MRVL | Long | 1.33:1 | -- | REJECT | -- | R/R <1.5:1; Trainium 3 loss; semi concentration |
| 2 | EQIX | Long | 1.04:1 | 1.69-2.00:1 | CONDITIONAL | 3-4% | Price to $870-900 OR 10Y <3.75% |
| 3 | ELV | Contrarian | 2.08:1 | 2.08:1 | CONDITIONAL (Tier 1B) | 5-7% | CMS final rate >=2.0% (by April 6) |
| 4 | IOT | Growth | 1.51:1 | 2.50:1 | CONDITIONAL | 5% | Price pullback to $33 or below |

### Conditional Pipeline Status (Final — 10/10 Cap)

**Three conditionals dropped this session**:
- B (Barrick Mining): Functionally redundant with AEM (correlation 0.80+). Replaced by ARMN in prior cycle.
- SYM (Symbotic): No imminent catalyst, no defined R/R, no urgency. Weakest conditional by thesis quality.
- DCO (Ducommun): Sub-WACC ROIC, low ADV, duplicative defense exposure with LHX. Lowest-priority conditional.

**Three new conditionals added this session**:
- EQIX (Data Center REIT): Prices below $870-900 or 10Y below 3.75% unlocks R/R above 1.5:1. Chain-adjacent but caps at 42%.
- ELV (Managed Care): CMS rate catalyst April 6. Tier 1B deployment priority. Zero correlation, VaR-reducing.
- IOT (IoT/Fleet AI): Price pullback from $35.36 to $30-33 improves R/R to 2.50-3.50:1. Q1 guidance gate. Application-layer diversification.

**Updated Conditional Pipeline (10/10, Binding Cap)**:

| Priority | Ticker | Type | Entry Range | Target Alloc | Key Trigger | VaR Impact | Status |
|---|---|---|---|---|---|---|---|
| 1 (VST contingency) | PANW | Cybersecurity | $145-170 | 5% | VST stop-out at $145 | VaR-neutral | Within entry |
| 2 (VIX norm.) | ZS | Cybersecurity | $155-175 | 7-8% | VIX <22 + 50-day SMA crossover + slot | VaR-modestly-increasing | Within entry |
| 3 (VST secondary) | VKTX | Biotech | $30-36 | 3% | VST stop-out | VaR-increasing | Within entry |
| 4 (FRO exit) | LNG | US LNG | $245-260 | 7% | FRO exit at $33 stop | VaR-neutral | Within entry |
| 5 (post-FDA) | LLY | Pharma/GLP-1 | $950-990 | 5% | FDA approval April 10 + slot | **VaR-reducing** | Within entry |
| 6 (post-CMS) | ELV | Managed Care | $275-298 | 5-7% | CMS rate >=2.0% (April 6) + slot | **VaR-reducing** | Within entry |
| 7 (preferred gold) | ARMN | Gold Mining | $17.50-20 | 3-4% | Post-March 11 earnings + VIX <22 + slot | VaR-increasing | Within entry |
| 8 (price pullback) | IOT | IoT/Fleet AI | $30-33 | 5% | Price pullback + VIX <22 + slot | VaR-increasing | Above entry ($35.36) |
| 9 (price pullback) | EQIX | Data Center REIT | $870-900 | 3-4% | Price pullback OR 10Y <3.75% + slot | VaR-modestly-increasing | Above entry ($937) |
| 10 (definition req.) | LEU | Nuclear Fuel | TBD | TBD | Must define by Cycle XI or drop | TBD | TBD |

**Pipeline Governance**:
- 10/10 hard cap enforced. No further additions without drops.
- 3-cycle hold limit applies. PANW, VKTX, LNG entering Cycle XII without catalyst progress will be dropped.
- LEU must define all parameters (entry range, target, stop, R/R, allocation, catalysts) by Cycle XI (March 8-9) or be dropped. This is mandatory.

---

## Reconciliation Against IC Memo 3

| Item | IC Decision | Booking Result | Status |
|---|---|---|---|
| MRVL | REJECT (Risk-confirmed) | Rejected; 4 grounds confirmed | ✓ |
| EQIX | CONDITIONAL (Priority 9) | Booked with 5 entry conditions; 3-4% target; $870-900 price gate | ✓ |
| ELV | CONDITIONAL (Tier 1B elevated) | Booked with 4 entry conditions; 5-7% target; R/R degradation framework defined | ✓ |
| IOT | CONDITIONAL (Priority 8) | Booked with 5 entry conditions; 5% target; price pullback $30-33 gate | ✓ |
| Conditional Drops | B, SYM, DCO | All three dropped; pipeline reduced to 10/10 cap | ✓ |
| Active Portfolio | HOLD all 10 at current allocations | All 10 positions unchanged; cash 20% | ✓ |
| Capital Deployed | $0 | Zero transactions; book unchanged | ✓ |
| Risk Flags (8 total) | All addressed | All 8 PM responses documented in prior ledger entry (2026-03-06_ledger-entry.md) | ✓ |

**Reconciliation Result**: Complete match. All IC memo directives booked exactly as approved.

---

## Key Risk Framework Updates (From IC Memo 3)

### VIX Escalation Thresholds

| VIX Level | Session Count | Classification | PM Action |
|---|---|---|---|
| 25-28 | Any | Advisory (current) | No allocation changes. Deploy only VaR-reducing names (LLY, ELV) if conditions met. |
| 28-35 | 1-2 sessions | Advisory (heightened) | Monitor. No allocation changes. Suspend all conditionals except VaR-reducing. |
| 28-35 | 3+ sessions | Critical | Consider VRT resize (13% to 10%). Evaluate reducing highest-beta. Cash floor 12%. |
| 35+ | Any session | Critical (immediate) | VRT resize mandatory (13% to 8-10%). All conditionals suspended. Cash floor 15%. |

**Current Status**: VIX at 29.49 (Session 1 above 28). Classification: Advisory (heightened). Escalation trigger: 3+ consecutive sessions above 28.

### April Dual-Catalyst Window (ELV + LLY)

Both CMS 2027 final rate (ELV, by April 6) and FDA approval (LLY, April 10) could trigger within same week. Portfolio at 10/10 slots (hard cap). Deployment pathway:

1. **If FRO stops out before April 6**: Slot opens. LNG designated FRO replacement (Tier 1). LLY and ELV remain gated by own conditions.
2. **If FRO holds, CMS fires positive**: No slot available. ELV remains conditional.
3. **If FRO holds, FDA fires positive**: LLY as Priority 1 could displace VRT (resize 13% to 8%, freeing 5% for LLY) if: (a) FDA approved, (b) VIX <22, (c) post-approval R/R >1.5:1.
4. **If both fire, only one slot available**: LLY deploys first (Priority 1). ELV queues for next slot.
5. **If both fire, two slots available**: Deploy both LLY (5%) and ELV (5%). Cash drops 20% to 10%. If this breaches 8% floor, ELV deploys at 5% only (cash to 8%).

Framework provides decision tree for every plausible April scenario without real-time improvisation.

### ELV R/R Threshold Framework (Risk Flag 2)

If ELV rally occurs above $298 on positive CMS rate:

- Entry $289 (current): R/R = $81/$39 = 2.08:1 ✓
- Entry $298: R/R = $72/$48 = 1.50:1 (minimum, $370 target holds)
- Entry $305: R/R at $370 = $65/$55 = 1.18:1 (below minimum; requires target revision to $387.50, analyst consensus $386.59 supports)
- Entry $310+: Target must exceed $392.50 (aggressive scenario, requires healthcare multiple expansion beyond base case)

**Deployment Rule**: If ELV entry exceeds $298 due to CMS rally, target must revise upward to maintain 1.5:1 R/R. Analyst consensus supports up to ~$305 entry. Above $305, deployment suspended pending revised thesis with updated target justification.

### AI-Adjacent Exposure Hard Cap: 42%

EQIX correlated with VRT, AVGO, CEG, VST. If EQIX deploys at 3-4%, combined AI-adjacent exposure reaches ~42% (current 39% chain + EQIX 3-4%). This is set as absolute hard cap.

**Deployment Rule**: If any existing AI chain position is exited or reduced before EQIX entry conditions are met, recalculate AI-adjacent total before deploying. EQIX only deploys if post-deployment total remains at or below 42%.

### FRO Stop Level: $33 (Maintained)

Risk Manager confirmed: Do not tighten to $34. Rationale:
- $34 stop reduces buffer to 1.6%, making stop-out nearly inevitable on normal volatility
- $33 corresponds to thesis invalidation point (sustained tanker rate decline)
- R/R 6.1:1 is portfolio best
- Max loss 0.18% NAV is trivial
- March 12 ex-dividend ($1.03/share, ~3.0% yield) provides modest offset
- **Decision**: FRO stop remains at $33 absolute.

---

## Directives Issued (from IC Memo 3)

### To Analysts

1. **Contrarian Analyst**: ELV is conditionally approved at Tier 1B (Priority 6). High-priority conditional. Monitor CMS 2027 final rate announcement daily (due April 6). Prepare updated R/R assessment immediately upon announcement. Critical thresholds: rate ≥2.0% bullish (deploy); 1.0-2.0% neutral (maintain); <1.0% triggers drop. Pre-calculate revised target at entry $298, $305, $310.

2. **Growth Analyst**: IOT conditionally approved at Priority 8, gated by price pullback to $33 or below. Portfolio construction classification corrected: IOT is AI application-layer diversifier, NOT counter-cyclical hedge. Monitor post-earnings consolidation. Historical median 30-day pullback after 15%+ gap-up suggests $31.70-$33.60 range. Track Q1 FY2027 guidance and AI Coach adoption. If breaks above $40 without pullback, reassess whether entry opportunity passed.

3. **Growth Analyst**: LEU must have fully defined parameters (entry range, target, stop, R/R, target allocation, catalyst triggers) by Cycle XI (March 8-9). If parameters not provided, LEU dropped from pipeline. Non-discretionary. Pipeline does not carry undefined names.

4. **Long Analyst**: MRVL rejected. Risk Manager concurs with all four grounds. Re-pitch criteria: (a) price <$80 for 2.0:1+ R/R, (b) Alchip/Trainium 3 dynamics explicitly addressed with primary sources, (c) semiconductor slot available. EQIX conditionally approved at Priority 9, gated by price pullback to $870-900. Monitor Q1 2026 bookings and AFFO growth.

5. **All Analysts**: Conditional pipeline restructured to 10/10. B, SYM, DCO dropped. EQIX, ELV, IOT added. No further additions possible without drops. 3-cycle hold limit enforced starting Cycle XI. Names without catalyst progress culled.

### To Risk Manager

6. **VIX Session Count Monitoring**: March 6 is Session 1 above 28. If VIX closes above 28 on March 9 (Session 2) and March 10 (Session 3), escalate VaR breach from Advisory to Critical per threshold table. Alert if VIX breaches 35 at any point.

7. **Credit Spread Monitor**: HY OAS at 3.00% is stable. If HY OAS widens above 3.50%, escalate to Critical regardless of VIX count. Signals transition from volatility to credit event.

8. **ELV Pre-Deployment Risk Assessment**: When CMS final rate announced (by April 6), provide updated VaR analysis and stress test with ELV at 5-7% at post-announcement price. Confirm VaR-reducing classification holds at actual deployment price.

9. **Pipeline Risk Acknowledged**: Conditional pipeline restructuring from 14 to 10 is confirmed as governance improvement. Risk characterizes rotation as "disciplined, not excessive churn." Acknowledged.

### To Bookkeeper

10. **No transactions this cycle.** Active portfolio unchanged. All 10 positions held at current allocations. Cash at 20%.

### To Investor Relations

11. **No portfolio changes to report.** Pipeline activity is internal. Active portfolio and NAV unchanged. If asked about elevated VIX and market conditions: Sterling maintains 20% cash as strategic reserve, all positions within stop-loss buffers, portfolio positioned for deployment into VaR-reducing opportunities as conditions normalize.

---

## Compliance/Risk Items (Final)

### Active Breaches

| # | Metric | Value | Guideline | Severity | Response |
|---|---|---|---|---|---|
| 1 | VaR 95% (1-day) | 2.65-3.02% | 2.0% | Advisory | VIX-driven. Session count monitoring initiated. Escalation at 3 sessions above 28. |
| 2 | VaR 99% (1-day) | 3.75-4.28% | 3.0% | Advisory | Mechanical consequence of VaR 95% breach. |
| 3 | AI Electrification Chain | 39% | 25% theme guideline | Advisory | Ceiling binding. EQIX chain-adjacent hard cap set at 42%. |

### Informational Items

| # | Item | Severity | Detail |
|---|---|---|---|
| 4 | Cash at 20% | Informational | Strategic advantage. April deployment pathway defined. Cash floor: 8% (normal), 12% (VIX Critical), 15% (VIX >35). |
| 5 | Max single-name 13.0% VRT | Informational | Within 15% guideline. 2 pp cushion. Subject to resize in April LLY scenario or VIX Critical escalation. |
| 6 | FRO stop proximity | Advisory | 4.5% buffer ($34.56 to $33). Max loss 0.18% NAV. $33 stop maintained per Risk. March 12 ex-date ($1.03 dividend). |
| 7 | Stagflation factor exposure | Advisory | Approximately neutral net. Brent $92.65+ strengthens energy/tanker, pressures growth names. |
| 8 | Drawdown from HWM | Informational | ~3.5-5.0%. Distance to -10% limit: ~5.0-6.5 pp. Adequate buffer. |
| 9 | VIX at 29.49 (Session 1 above 28) | Advisory (heightened) | Escalation trigger: 3 sessions above 28 = Critical. Immediate Critical if VIX >35. |
| 10 | Conditional pipeline at 10/10 | Informational | Governance improvement from 14. Binding cap enforced. 3-cycle hold limit active. |
| 11 | Gold mining concentration cap 10% | Advisory | AEM 5% active. ARMN 3-4% conditional. Combined max 8-9%, within cap. B dropped. |
| 12 | Healthcare sector introduction | Informational | ELV at 5-7% conditional would be Sterling's first healthcare exposure. Zero correlation, VaR-reducing. |
| 13 | April dual-catalyst window | Advisory | CMS (April 6) + FDA (April 10). Max deployment 10-12%. Slot constraint addressed via VRT resize pathway. 8% cash floor. |
| 14 | ELV R/R threshold | Informational | Max entry $298 at $370 target for 1.5:1 R/R. Above $298: target revision required. Above $305: deployment suspended. |
| 15 | LEU undefined | Informational | Must define by Cycle XI or drop. Pipeline slot at risk. |
| 16 | Brent at $92.65+ | Informational | Strengthens FRO, CEG, VST. Increases stagflation risk for growth. Portfolio net-neutral. |
| 17 | No capital deployed this cycle | Confirmed | All decisions conditional. Portfolio risk profile unchanged. |

---

## Next IC Date

**Cycle XI**: March 8-9, 2026

**Priority Agenda**:
1. VIX session count check: Did VIX close above 28 on March 7? (Session 2 status)
2. HY OAS trend: Widening above 3.00%? Credit stress emerging?
3. FRO pre-ex-date assessment (ex-date March 12): Stop buffer, dividend capture outlook
4. ARMN post-earnings assessment (March 11 Q4/FY2025): Production, margins, AISC, Soto Norte/Marmato timelines
5. LEU parameter definition deadline — Growth Analyst must deliver or LEU drops
6. PANW, VKTX, LNG 3-cycle hold limit review (approaching Cycle XII limit)
7. Gold price trajectory and AEM position assessment ($5,500 resize trigger)
8. Intel Vision countdown (March 31, ~23 days)
9. Oil price trajectory (Brent $92+; $100+ scenario planning)
10. ZS technical trend assessment (50-day SMA crossover watch)
11. ELV CMS rate countdown (by April 6, ~29 days)
12. LLY FDA countdown (April 10, ~33 days)
13. IOT post-earnings price action monitoring (consolidation toward $33?)
14. Stagflation factor monitoring (NFP aftermath, Fed response, real wage growth)

---

## Summary: Cycle X Pipeline Addendum II Booking

**Portfolio Status**: All 10 active positions HOLD at current allocations. 80% deployed, 20% cash.

**Capital Deployed Today**: $0.

**Transactions Executed**: None.

**New Conditional Approvals**: 3 names (EQIX, ELV, IOT). All gated by strict entry conditions. No capital deployed.

**Rejections**: 1 name (MRVL, Risk-confirmed on all four grounds).

**Conditional Drops**: 3 names (B, SYM, DCO). Pipeline reduced from 14 to 10 names (hard cap enforced).

**Portfolio Risk Profile**: Unchanged from prior booking.

**Reconciliation Status**: Complete. All IC memo directives booked exactly as approved. 0 discrepancies.

**Current-Holdings.json**: No update required. as_of date, prices, and allocations unchanged.

---

**Booked by**: Bookkeeper | **Source**: 2026-03-06_ic-memo-3.md (Cycle X Pipeline Addendum II, FINAL 23:59 UTC) | **Date**: 2026-03-06 23:59 UTC | **Status**: Complete

**Next Booking**: Cycle XI (March 8-9, 2026)
